Skip to main content
Premium Trial:

Request an Annual Quote

Biocept Q2 Revenues Fall 60 Percent

NEW YORK (GenomeWeb) – Biocept today reported a 60 percent drop in its second quarter revenues.

In a Form 10-Q filed with the US Securities and Exchange Commission, the San Diego-based company said that for the three months ended June 30, revenues fell to $19,245 from $48,369 in the year-ago quarter. The decline, it said, resulted primarily from lower sample volume related to a collaboration with the Dana-Farber Cancer Institute that is approaching completion.

Biocept's net loss for the quarter was $3 million, or $.67 per share, compared to a net loss of $2 million, or $10.83 per share in Q2 2013. In the recently completed quarter, the firm used approximately 4.4 million shares to calculate its loss on a per-share basis, compared to 182,304 shares in the year-ago period. Biocept went public in February with an offering of 1.9 million shares.

The company said it had $12.5 million in cash and cash equivalents as of the end of Q2. In May Biocept entered into a $10 million loan and security agreement with Oxford Finance.

In afternoon trading on Monday, shares of Biocept were down about 4 percent on the Nasdaq at $4.70.

The Scan

Dropped Charges

The US Justice Department has dropped visa fraud charges against five Chinese researchers, according to the Wall Street Journal.

More Kids

The Associated Press says Moderna is expanding its SARS-CoV-2 vaccine study to included additional children and may include even younger children.

PNAS Papers on Rat Clues to Human Migration, Thyroid Cancer, PolyG-DS

In PNAS this week: ancient rat genome analysis gives hints to human migrations, WDR77 gene mutations in thyroid cancer, and more.

Purnell Choppin Dies

Purnell Choppin, a virologist who led the Howard Hughes Medical Institute, has died at 91, according to the Washington Post.